Table 2.
Univariate and multivariate analysis of Cox proportional HR of relevant tumor and treatment variables with local recurrence after oligometastatic tumor radioablation
| Univariate |
Multivariate |
|||||||
|---|---|---|---|---|---|---|---|---|
| 95% CI |
95% CI |
|||||||
| HR | Lower | Upper | P | HR | Lower | Upper | P | |
| Histology | ||||||||
| Other histology (ref.) | ||||||||
| Breast | 0.298 | 0.065 | 1.362 | .118 | 4.4991 | 0.042 | 1.155 | .074 |
| Colo-rectal cancer | 2.681 | 1.158 | 6.209 | .021 | 0.4121 | 0.962 | 6.117 | .060 |
| NSCLC | 1.716 | 0.713 | 4.128 | .228 | 0.5005 | 0.753 | 5.297 | .164 |
| Prostate | 0.285 | 0.078 | 1.035 | .056 | 2.7172 | 0.091 | 1.485 | .160 |
| Lesion site | ||||||||
| Bone (ref.) | ||||||||
| Liver | 2.446 | 0.632 | 9.463 | .195 | 1.9025 | 0.096 | 2.853 | .456 |
| Lymph nodes | 1.462 | 0.544 | 3.925 | .451 | 0.8321 | 0.394 | 3.661 | .746 |
| Lung | 2.825 | 1.095 | 7.290 | .032 | 0.5656 | 0.593 | 5.262 | .306 |
| Soft tissues | 4.644 | 1.625 | 13.269 | .004 | 0.3506 | 0.902 | 9.018 | .074 |
| Volume | ||||||||
| GTV (cm3) continuous | 1.009 | 1.002 | 1.016 | .015 | 0.9910 | 0.998 | 1.020 | .091 |
| Baseline SUVmax | ||||||||
| SUVmax continuous | 1.011 | 0.981 | 1.043 | .475 | 0.9815 | 0.979 | 1.060 | .352 |
| Systemic therapy | ||||||||
| Adjuvant systemic therapy | 1.171 | 0.607 | 2.258 | .637 | 0.1599 | 0.832 | 46.980 | .075 |
| PTV coverage (D99%) | ||||||||
| D99% ≥23 Gy (ref.) | ||||||||
| PMDS<23-18 Gy | 1.865 | 0.979 | 3.555 | .058 | 0.5813 | 0.795 | 3.719 | .168 |
| PMDS<18 Gy V99 ≥60% | 1.008 | 0.241 | 4.216 | .992 | 1.3043 | 0.144 | 4.062 | .755 |
| PMDS<18 Gy V99 <60% | 3.361 | 1.304 | 8.664 | .012 | 0.3137 | 1.072 | 9.470 | .037 |
Abbreviations: CI = confidence interval; GTV = gross tumor volume; HR = hazard ratio; NSCLC = non-small cell lung cancer; PMDS = perfusion-modulated dose sculpting; PTV = planning target volume; SUV = standardized uptake volume.